94 results on '"Dorsey, Bruce D."'
Search Results
52. Abstract 3574: Identification and preclinical characterization of CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase, in lymphoma and non-small cell lung cancer models
53. Corrigendum to “Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models” [Bioorg. Med. Chem. Lett. 21 (2011) 463]
54. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
55. Synthesis and Pharmacological Evaluation of N-(3-(1H-Indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a Potent Antimitotic Agent
56. Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
57. Abstract 2503: PI3K/Akt/mTOR activity is a major determinant for the sensitivity of NPM-ALK (+) anaplastic large cell lymphoma cells to ALK inhibition
58. Use of cMet Crystal Structures to Identify Potential Drug‐Resistant Mutants
59. Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
60. Design, Synthesis, and BiologicalEvaluation of SulfonylAcrylonitriles as Novel Inhibitors of Cancer Metastasis and Spread.
61. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells
62. Efficient Synthesis of Substituted Biaryl Anilines and Biaryl Phenols via a Suzuki Cross-Coupling Reaction.
63. Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists
64. Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors
65. Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
66. ChemInform Abstract: Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors.
67. Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors
68. Efficient synthesis of substituted biaryl anilines and biaryl phenols via a Suzuki cross-coupling reaction
69. Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates
70. Metabolite–P450 Complex Formation by Methylenedioxyphenyl HIV Protease Inhibitors in Rat and Human Liver Microsomes
71. L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
72. A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site
73. A practical synthesis of 5‐(chloromethyl)furo[2,3‐b]pyridine, a key intermediate for the HIV protease inhibitor, L‐754,394
74. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site
75. Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors
76. L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor
77. Synthesis, antiviral activity, and bioavailability studies of γ-lactam derived HIV protease inhibitors
78. A concise and enantioselective synthesis of novel HIV-1 protease transition state mimics
79. A Selective, Orally Bioavailable1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor ofJanus Kinase 2 for Use inAnticancer Therapy: Discovery of CEP-33779.
80. Discovery of an OrallyEfficacious Inhibitor of Anaplastic Lymphoma Kinase.
81. Corrigendum to “Novel 2,3,4,5-tetrahydro-benzo[ d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models” [Bioorg. Med. Chem. Lett. 21 (2011) 463]
82. Is there a scaffolding domain within the structure of the immunosuppressive agent cyclosporin a (CsA)? Studies of the cyclophilin binding domain of CsA
83. Synthesis of (-)-bertyadionol
84. Preparation, reactivity, and spectral properties of 1,3-dioxin vinylogous esters: versatile .beta.-ketovinyl cation equivalents
85. Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNA.
86. Chapter 11 - Evolution of a Synthetic Strategy, Part II: Total Synthesis of (-)-Casbene and (-)-Bertyadionol
87. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors
88. Structure-Activity Relationships and Discovery of ( S )-5-( tert -Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5- h ]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer.
89. Structure-Activity Relationships and Discovery of ( S )-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6 H -pyrido[1,2- h ][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer.
90. The identification of highly efficacious functionalised tetrahydrocyclopenta[ c ]pyrroles as inhibitors of HBV viral replication through modulation of HBV capsid assembly.
91. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery.
92. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
93. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles.
94. Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.